Peer-reviewed veterinary case report
Etanercept does not prevent pancreatitis after ERCP in dogs
By Buscaglia, Jonathan M et al.·Published in JOP : Journal of the pancreas·2008·Johns Hopkins University School of Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Etanercept, a TNF-alpha binding agent, is ineffective in the prevention of post-ERCP pancreatitis in canines.
- Species:
- dog
Plain-English summary
A group of dogs underwent a procedure called endoscopic retrograde pancreatography (ERP) to see if a medication called etanercept could prevent pancreatitis, which is inflammation of the pancreas. After the procedure, all dogs showed signs of mild to moderate pancreatitis, with increased levels of certain enzymes in their blood. Unfortunately, the dogs that received etanercept did not show any improvement compared to those that did not receive the treatment. This means etanercept was not effective in preventing pancreatitis in these dogs.
People also search for: dog pancreatitis treatment · etanercept for dogs · post-ERCP pancreatitis in dogs
Abstract
CONTEXT: The incidence of post-ERCP pancreatitis is 1-22%. It continues to be a difficult problem for endoscopist and patient. Uncovering an agent that may be used to prevent its occurrence is critical. OBJECTIVE: The aim of our study was to investigate the role of etanercept in the prevention of post-ERCP pancreatitis. DESIGN: Endoscopic retrograde pancreatography (ERP)-induced injury was performed in dogs using a previously established endoscopic model of post-ERCP pancreatitis. ANIMALS: Eight study dogs underwent ERP: 4 were pre-treated with etanercept one day before the procedure and 4 were untreated. In addition, three control dogs not undergoing ERP were also studied. MAIN OUTCOME MEASURES: Serum levels of amylase, lipase, and TNF-alpha, as well as the ratio of urinary trypsinogen activation peptide (TAP) and urinary creatinine, were measured before and after ERP. Necropsy was performed on post-operative day 5. All pancreatic specimens were graded by two blinded pathologists according to a validated scoring system. RESULTS: Eight study dogs developed mild to moderate clinical pancreatitis with hyperamylasemia (11,538+/-4,065 U/L vs. 701+/-157 U/L; post-ERP peak levels vs. baseline values: P<0.001) and hyperlipasemia (3,637+/-2,333 U/L vs. 246+/-125 U/L; P=0.003). Mean total injury score was significantly elevated in study dogs compared to control dogs (6.16+/-1.85 vs. 1.06+/-0.49; P=0.001). There were escalating total injury scores concordant with more elaborate methods of endoscopically-induced injury although the trend did not reach the statistical significance (P=0.223). When comparing untreated to etanercept-treated dogs, there were no significant differences in serum amylase levels (P=0.903), serum lipase levels (P=0.771), TAP/creatinine urinary ratio (P=0.912), and pancreatic injury score (P=0.324). CONCLUSION: Etanercept is ineffective in prevention of mild to moderate post-ERCP pancreatitis in canines. ERP-induced pancreatic injury can be used as a reliable animal model for studies investigating therapy and prevention of post-ERCP pancreatitis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/18648137/